3-Ethyl-s-triazolo<4,3-a>pyrazin | 33590-18-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-Ethyl-s-triazolo<4,3-a>pyrazin
• 英文别名: 3-Ethyl-[1,2,4]triazolo[4,3-a]pyrazine
• CAS: 33590-18-0
• 化学式: C₇H₈N₄
• mdl: MFCD11856758
• 分子量: 148.167
• InChiKey: FWGLTJTVQUURRX-UHFFFAOYSA-N

物化性质

• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Ethyl-s-triazolo<4,3-a>pyrazin 在 5%-palladium/activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 以137 g的产率得到3-乙基-5,6,7,8-四氢-1,2,4-三唑并[4,3-a]吡嗪
  参考文献：
  名称：

  5,6,7,8-四氢[1,2,4]三唑并[4,3-a]吡嗪的聚焦小分子库：药物化学之家的一块砖

  摘要：

  本文重点介绍了哌嗪稠合三唑类药物发展中的挑战和机遇。阐述了基于[1,2,4]三唑并[4,3- a ]吡嗪平台的药物化学相关构建模块的方法。该方法可以从市售的廉价试剂开始快速、多克地获得目标衍生物。这些方法用于创建一个小型的三唑并吡嗪文库，其中 3 位具有多种取代基。显示了文库成员进一步合成应用用于药物合成的潜力。

  DOI：

  10.1007/s10593-023-03213-y

文献信息

• NOVEL ANTIMICROBIALS
  申请人：Jain Rajesh

  公开号：US20110245258A1

  公开（公告）日：2011-10-06

  The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H. influenza, Moraxella, acid-fast organisms such as Mycobacterium tuberculosis as well as Linezolid resistant species of Staphylococcus and Enterococcus.

  本发明涉及公式I的新型苯基噁唑啉酮化合物，它们的药学上可接受的类似物、互变异构体、立体异构体、多晶形态、前药、代谢物、盐或其溶剂。本发明还涉及合成公式I的新化合物或其药学上可接受的类似物、互变异构体、立体异构体、多晶形态、前药、代谢物、盐或其溶剂的过程。本发明还提供了包含公式I的新化合物的制药组合物和使用它们的方法。本发明的化合物是抗微生物剂，对多种需氧和/或厌氧革兰阳性和/或革兰阴性病原体具有有效作用，如金黄色葡萄球菌、链球菌、肠球菌、拟杆菌、梭菌、流感嗜血杆菌、摩拉克斯氏菌、抗利多霉素的金黄色葡萄球菌和肠球菌等耐药菌。
• TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF
  申请人：EPIZYME, INC.

  公开号：US20150344434A1

  公开（公告）日：2015-12-03

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5 mediated disorders are also described.

  本文描述了公式（A）的化合物，其药学上可接受的盐以及它们的药物组合物。本发明的化合物对于抑制PRMT5活性是有用的。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。
• Sufonamides and Uses Thereof
  申请人：Saunders Jeffrey O.

  公开号：US20080261970A1

  公开（公告）日：2008-10-23

  Compounds of formula (I), including methods of making and methods of using are described in formula (I).
• AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Epizyme, Inc.

  公开号：US20200039998A1

  公开（公告）日：2020-02-06

  The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
• COMBINATION THERAPIES WITH EHMT2 INHIBITORS
  申请人：Epizyme, Inc.

  公开号：US20200054635A1

  公开（公告）日：2020-02-20

  The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.